{
    "xml": "<topic id=\"PHP5452\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/cetuximab\" basename=\"cetuximab\" title=\"CETUXIMAB\">\n<title>CETUXIMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1334\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/cetuximab\">Cetuximab</xref>\n</p>\n<data name=\"vtmid\">409401002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP51703\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/cetuximab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated</p>\n<p outputclass=\"therapeuticIndication\">Treatment of locally advanced squamous cell cancer of the head and neck (in combination with radiotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of recurrent or metastatic squamous cell cancer of the head and neck (in combination with platinum-based chemotherapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (initiated by a specialist)</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51752\" outputclass=\"importantSafetyInformation\" rev=\"1.11\" parent=\"/drugs/cetuximab\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)</p>\n<p>Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Patients must receive an antihistamine and a corticosteroid at least one hour before infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51766\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/cetuximab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">\n<i>RAS</i> mutated colorectal tumours (or if <i>RAS</i> tumour status unknown)</ph>; <ph outputclass=\"contraindication\">combination of cetuximab with oxaliplatin-containing chemotherapy is contra-indicated in patients with metastatic colorectal cancer who have mutant or unknown <i>RAS</i> status</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51790\" outputclass=\"cautions\" rev=\"1.8\" parent=\"/drugs/cetuximab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cardiopulmonary disease</ph>; <ph outputclass=\"caution\">cardiovascular disease</ph>; <ph outputclass=\"caution\">history of keratitis</ph>; <ph outputclass=\"caution\">pulmonary disease&#8212;discontinue if interstitial lung disease</ph>; <ph outputclass=\"caution\">risk factors for keratitis</ph>; <ph outputclass=\"caution\">severe dry eye</ph>; <ph outputclass=\"caution\">ulcerative keratitis (including contact lens use)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51676\" outputclass=\"interactions\" rev=\"1.15\" parent=\"/drugs/cetuximab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (cetuximab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51596\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/cetuximab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acne</ph>; <ph outputclass=\"sideEffect\">aseptic meningitis</ph>; <ph outputclass=\"sideEffect\">blepharitis</ph>; <ph outputclass=\"sideEffect\">bronchospasm</ph>; <ph outputclass=\"sideEffect\">chills</ph>; <ph outputclass=\"sideEffect\">conjunctivitis</ph>; <ph outputclass=\"sideEffect\">desquamation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypertrichosis</ph>; <ph outputclass=\"sideEffect\">hypocalcaemia</ph>; <ph outputclass=\"sideEffect\">hypomagnesaemia</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">infusion-related reactions</ph>; <ph outputclass=\"sideEffect\">keratitis</ph>; <ph outputclass=\"sideEffect\">nail disorders</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">severe (sometimes fatal) hypersensitivity reactions (possibly delayed onset)</ph>; <ph outputclass=\"sideEffect\">shock</ph>; <ph outputclass=\"sideEffect\">skin reactions</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51784\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/cetuximab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51667\" outputclass=\"pregnancy\" parent=\"/drugs/cetuximab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if potential benefit outweighs risk&#8212;no information available.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51815\" outputclass=\"breastFeeding\" parent=\"/drugs/cetuximab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid breast-feeding during and for 2 months after treatment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51610\" outputclass=\"preTreatmentScreening\" rev=\"1.13\" parent=\"/drugs/cetuximab\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>Evidence of non-mutated (wild-type) <i>RAS</i> status (at exons 2, 3 and 4 of <i>KRAS</i> and <i>NRAS</i>) is required before cetuximab is initiated for the treatment of metastatic colorectal cancer, and should be determined by an experienced laboratory using a validated test method.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51834\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/drugs/cetuximab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Resuscitation facilities should be available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51516\" outputclass=\"nationalFunding\" rev=\"1.33\" parent=\"/drugs/cetuximab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA145</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008)</p>\r\n<p>Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA145\">www.nice.org.uk/TA145</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA172</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009)</p>\r\n<p>Cetuximab in combination with platinum-based chemotherapy is <b>not</b> recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA172\">www.nice.org.uk/TA172</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA176</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)</p>\r\n<p>Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:</p>\r\n<ul>\r\n<li>the primary tumour has been resected or is potentially operable;</li>\r\n<li>the metastatic disease is confined to the liver and is unresectable; and</li>\r\n<li>the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.</li>\r\n</ul>\r\n<p>In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.</p>\r\n<p>In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.</p>\r\n<p>Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA176\">www.nice.org.uk/TA176</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA242</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</p>\r\n<p>Cetuximab monotherapy or combination chemotherapy is <b>not</b> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA242\">www.nice.org.uk/TA242</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (December 2014) that cetuximab (<i>Erbitux</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland, in combination with irinotecan or oxaliplatin-based chemotherapy, for the treatment of RAS wild-type metastatic colorectal cancer in patients who have not previously received chemotherapy for their metastatic disease (first-line treatment).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5452-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/cetuximab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75856\" title=\"Solution for infusion\" namespace=\"/drugs/cetuximab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1334\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/cetuximab\" title=\"Cetuximab\" count=\"1\" rel=\"link\">Cetuximab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75856\" namespace=\"/drugs/cetuximab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5452",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/cetuximab",
    "basename": "cetuximab",
    "title": "CETUXIMAB",
    "interactants": [
        {
            "id": "bnf_int_1334",
            "label": "Cetuximab"
        }
    ],
    "vtmid": "409401002",
    "drugClassification": [
        "Monoclonal antibodies (antineoplastic)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated",
                        "html": "Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated"
                    },
                    {
                        "textContent": "Treatment of locally advanced squamous cell cancer of the head and neck (in combination with radiotherapy)",
                        "html": "Treatment of locally advanced squamous cell cancer of the head and neck (in combination with radiotherapy)"
                    },
                    {
                        "textContent": "Treatment of recurrent or metastatic squamous cell cancer of the head and neck (in combination with platinum-based chemotherapy)",
                        "html": "Treatment of recurrent or metastatic squamous cell cancer of the head and neck (in combination with platinum-based chemotherapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>",
                        "ageGroup": "(initiated by a specialist)"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)",
                "textContent": "Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.",
                "html": "<p>Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.</p>"
            },
            {
                "type": "importantSafetyInformation",
                "textContent": "Patients must receive an antihistamine and a corticosteroid at least one hour before infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist.",
                "html": "<p>Patients must receive an antihistamine and a corticosteroid at least one hour before infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "RAS mutated colorectal tumours (or if RAS tumour status unknown)",
                "html": "<i>RAS</i> mutated colorectal tumours (or if <i>RAS</i> tumour status unknown)"
            },
            {
                "type": "contraindications",
                "textContent": "combination of cetuximab with oxaliplatin-containing chemotherapy is contra-indicated in patients with metastatic colorectal cancer who have mutant or unknown RAS status",
                "html": "combination of cetuximab with oxaliplatin-containing chemotherapy is contra-indicated in patients with metastatic colorectal cancer who have mutant or unknown <i>RAS</i> status"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cardiopulmonary disease",
                "html": "Cardiopulmonary disease"
            },
            {
                "type": "cautions",
                "textContent": "cardiovascular disease",
                "html": "cardiovascular disease"
            },
            {
                "type": "cautions",
                "textContent": "history of keratitis",
                "html": "history of keratitis"
            },
            {
                "type": "cautions",
                "textContent": "pulmonary disease&#8212;discontinue if interstitial lung disease",
                "html": "pulmonary disease&#8212;discontinue if interstitial lung disease"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for keratitis",
                "html": "risk factors for keratitis"
            },
            {
                "type": "cautions",
                "textContent": "severe dry eye",
                "html": "severe dry eye"
            },
            {
                "type": "cautions",
                "textContent": "ulcerative keratitis (including contact lens use)",
                "html": "ulcerative keratitis (including contact lens use)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (cetuximab).",
                "html": "<p>Appendix 1 (cetuximab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Acne",
                        "html": "Acne",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "aseptic meningitis",
                        "html": "aseptic meningitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "blepharitis",
                        "html": "blepharitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bronchospasm",
                        "html": "bronchospasm",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "chills",
                        "html": "chills",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctivitis",
                        "html": "conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "desquamation",
                        "html": "desquamation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertrichosis",
                        "html": "hypertrichosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypocalcaemia",
                        "html": "hypocalcaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypomagnesaemia",
                        "html": "hypomagnesaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "infusion-related reactions",
                        "html": "infusion-related reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "keratitis",
                        "html": "keratitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nail disorders",
                        "html": "nail disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "severe (sometimes fatal) hypersensitivity reactions (possibly delayed onset)",
                        "html": "severe (sometimes fatal) hypersensitivity reactions (possibly delayed onset)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "shock",
                        "html": "shock",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "skin reactions",
                        "html": "skin reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if potential benefit outweighs risk&#8212;no information available.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Use only if potential benefit outweighs risk&#8212;no information available.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid breast-feeding during and for 2 months after treatment&#8212;no information available.",
                "html": "<p>Avoid breast-feeding during and for 2 months after treatment&#8212;no information available.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "Evidence of non-mutated (wild-type) RAS status (at exons 2, 3 and 4 of KRAS and NRAS) is required before cetuximab is initiated for the treatment of metastatic colorectal cancer, and should be determined by an experienced laboratory using a validated test method.",
                "html": "<p>Evidence of non-mutated (wild-type) <i>RAS</i> status (at exons 2, 3 and 4 of <i>KRAS</i> and <i>NRAS</i>) is required before cetuximab is initiated for the treatment of metastatic colorectal cancer, and should be determined by an experienced laboratory using a validated test method.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Resuscitation facilities should be available.",
                "html": "<p>Resuscitation facilities should be available.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA145",
                        "label": "www.nice.org.uk/TA145"
                    }
                ],
                "fundingIdentifier": "NICE TA145",
                "textContent": "Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.\n\nwww.nice.org.uk/TA145",
                "html": "<p outputclass=\"title\">Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008)</p> <p>Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA145\">www.nice.org.uk/TA145</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA172",
                        "label": "www.nice.org.uk/TA172"
                    }
                ],
                "fundingIdentifier": "NICE TA172",
                "textContent": "Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009) Cetuximab in combination with platinum-based chemotherapy is not recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.\n\nwww.nice.org.uk/TA172",
                "html": "<p outputclass=\"title\">Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009)</p> <p>Cetuximab in combination with platinum-based chemotherapy is <b>not</b> recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA172\">www.nice.org.uk/TA172</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA176",
                        "label": "www.nice.org.uk/TA176"
                    }
                ],
                "fundingIdentifier": "NICE TA176",
                "textContent": "Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009) Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances: the primary tumour has been resected or is potentially operable; the metastatic disease is confined to the liver and is unresectable; and the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab. In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative. In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin. Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.\n\nwww.nice.org.uk/TA176",
                "html": "<p outputclass=\"title\">Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)</p> <p>Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:</p> <ul> <li>the primary tumour has been resected or is potentially operable;</li> <li>the metastatic disease is confined to the liver and is unresectable; and</li> <li>the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.</li> </ul> <p>In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.</p> <p>In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.</p> <p>Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA176\">www.nice.org.uk/TA176</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA242",
                        "label": "www.nice.org.uk/TA242"
                    }
                ],
                "fundingIdentifier": "NICE TA242",
                "textContent": "Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) Cetuximab monotherapy or combination chemotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.\n\nwww.nice.org.uk/TA242",
                "html": "<p outputclass=\"title\">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</p> <p>Cetuximab monotherapy or combination chemotherapy is <b>not</b> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA242\">www.nice.org.uk/TA242</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75856",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1334",
                "label": "Cetuximab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75856",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}